世界のパーキンソン病治療の市場規模は、2024年に56億5000万ドルと推定され、2025年から2030年にかけて5.04%のCAGRで成長すると予想されます。主な推進要因には、神経保護療法、RNAベースの治療、薬物送達システムの改善など、医薬品開発の進歩があります。認知度の向上、政府による支援的な取り組み、償還政策により、治療薬の採用がさらに促進されています。さらに、運動症状と非運動症状に対処する革新的な治療法の強力なパイプラインが、拡大する患者ベースに合わせて市場の潜在力を拡大します。
目次
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Drug
1.2.2. Distribution Channel
1.2.3. Regional Scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Regional outlook
2.4. Competitive Insights
Chapter 3. Parkinson’s Disease Treatment Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Advancements in treatment options
3.2.1.2. Rising prevalence of Parkinson’s disease
3.2.1.3. Increased research and investment
3.2.2. Market Restraint Analysis
3.2.2.1. High treatment costs
3.2.2.2. Regulatory and Reimbursement Challenges
3.3. Parkinson’s Disease Treatment Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
Chapter 4. Parkinson’s Disease Treatment Market: Drug Class Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Parkinson’s Disease Treatment Market: Drug Class Movement Analysis
4.3. Parkinson’s Disease Treatment Market by Drug Class (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Carbidopa-Levodopa
4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Dopamine Agonists
4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. MAO-B Inhibitors
4.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. COMT Inhibitors
4.8.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.9. Anticholinergics
4.9.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.10. Others
4.10.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Parkinson’s Disease Treatment Market: Distribution Channel Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Parkinson’s Disease Treatment Market: Distribution Channel Movement Analysis
5.3. Parkinson’s Disease Treatment Market by Distribution Channel Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 To 2030 for the following
5.5. Hospital Pharmacy
5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Retail Pharmacy
5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Online Pharmacy
5.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Parkinson’s Disease Treatment Market: Regional Estimates & Trend Analysis
6.1. Regional Dashboard
6.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
6.3. North America
6.3.1. U.S.
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework/ reimbursement structure
6.3.1.3. Competitive scenario
6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.3.2. Canada
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework/ reimbursement structure
6.3.2.3. Competitive scenario
6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.3.3. Mexico
6.3.3.1. Key country dynamics
6.3.3.2. Regulatory framework/ reimbursement structure
6.3.3.3. Competitive scenario
6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework/ reimbursement structure
6.4.1.3. Competitive scenario
6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Germany
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework/ reimbursement structure
6.4.2.3. Competitive scenario
6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. France
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework/ reimbursement structure
6.4.3.3. Competitive scenario
6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4. Italy
6.4.4.1. Key country dynamics
6.4.4.2. Regulatory framework/ reimbursement structure
6.4.4.3. Competitive scenario
6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.4.5. Spain
6.4.5.1. Key country dynamics
6.4.5.2. Regulatory framework/ reimbursement structure
6.4.5.3. Competitive scenario
6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.4.6. Norway
6.4.6.1. Key country dynamics
6.4.6.2. Regulatory framework/ reimbursement structure
6.4.6.3. Competitive scenario
6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.4.7. Sweden
6.4.7.1. Key country dynamics
6.4.7.2. Regulatory framework/ reimbursement structure
6.4.7.3. Competitive scenario
6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.4.8. Denmark
6.4.8.1. Key country dynamics
6.4.8.2. Regulatory framework/ reimbursement structure
6.4.8.3. Competitive scenario
6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.5.2. China
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.5.3. India
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/ reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.5.4. Australia
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework/ reimbursement structure
6.5.4.3. Competitive scenario
6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.5.5. South Korea
6.5.5.1. Key country dynamics
6.5.5.2. Regulatory framework/ reimbursement structure
6.5.5.3. Competitive scenario
6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.5.6. Thailand
6.5.6.1. Key country dynamics
6.5.6.2. Regulatory framework/ reimbursement structure
6.5.6.3. Competitive scenario
6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.6.2. Argentina
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
6.7.2. Saudi Arabia
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
6.7.3. UAE
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/ reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
6.7.4. Kuwait
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/ reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Market Participant Categorization
7.2. Recent Developments & Impact Analysis by Key Market Participants
7.3. Company Market Share Analysis, 2024
7.4. Key Company Profiles
7.4.1. Cerevel Therapeutics
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. Novartis AG
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. Teva Pharmaceutical Industries Ltd.
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. Merck & Co., Inc.
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. GlaxoSmithKline plc. (GSK)
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. AbbVie, Inc.
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. H. Lundbeck A/S
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. Amneal Pharmaceuticals LLC
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives
7.4.9. Supernus Pharmaceuticals, Inc.
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Product benchmarking
7.4.9.4. Strategic initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Regulatory Framework
Table 4 Global Parkinson’s disease treatment market, By Region, 2018 - 2030 (USD Million)
Table 5 Global Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 6 Global Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 7 North America Parkinson’s disease treatment market, By Country, 2018 - 2030 (USD Million)
Table 8 North America Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 9 North America Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 10 U.S. Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 11 U.S. Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 12 Canada Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 13 Canada Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 14 Mexico Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 15 Mexico Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 16 Europe Parkinson’s disease treatment market, By Country, 2018 - 2030 (USD Million)
Table 17 Europe Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 18 Europe Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 19 UK Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 20 UK Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 21 Germany Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 22 Germany America Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 23 France Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 24 France Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 25 Spain Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 26 Spain Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 27 Italy Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 28 Italy Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 29 Denmark Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 30 Denmark Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 31 Sweden Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 32 Sweden Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 33 Norway Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 34 Norway Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 35 Asia Pacific Parkinson’s disease treatment market, By Country, 2018 - 2030 (USD Million)
Table 36 Asia Pacific Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 37 Asia Pacific Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 38 China Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 39 China Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 40 Japan Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 41 Japan Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 42 India Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 43 India Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 44 South Korea Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 45 South Korea Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 46 Australia Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 47 Australia Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 48 Thailand Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 49 Thailand Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 50 Latin America Parkinson’s disease treatment market, By Country, 2018 - 2030 (USD Million)
Table 51 Latin America Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 52 Latin America Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 53 Brazil Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 54 Brazil Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 55 Argentina Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 56 Argentina Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 57 MEA Parkinson’s disease treatment market, By Country, 2018 - 2030 (USD Million)
Table 58 MEA Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 59 MEA Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 60 South Africa Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 61 South Africa Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 62 Saudi Arabia Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 63 Saudi Arabia Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 64 UAE Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 65 UAE Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 66 Kuwait Parkinson’s disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
Table 67 Kuwait Parkinson’s disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research approaches
Fig. 2 Value chain-based sizing & forecasting
Fig. 3 Market formulation & validation
Fig. 4 Parkinson’s disease treatment market segmentation
Fig. 5 Market driver analysis (current & future impact)
Fig. 6 Market restraint analysis (current & future impact)
Fig. 7 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 8 Porter’s five forces analysis
Fig. 9 Parkinson’s disease treatment market: Drug class outlook and key takeaways
Fig. 10 Parkinson’s disease treatment market: Drug class movement analysis
Fig. 11 Carbidopa-Levodopa market estimates and forecast, 2018-2030 (USD Million)
Fig. 12 Dopamine Agonist market estimates and forecast, 2018-2030 (USD Million)
Fig. 13 MAO-B Inhibitors market estimates and forecast, 2018-2030 (USD Million)
Fig. 14 COMT inhibitors market estimates and forecast, 2018-2030 (USD Million)
Fig. 15 Anticholinergics market estimates and forecast, 2018-2030 (USD Million)
Fig. 16 Others market estimates and forecast, 2018-2030 (USD Million)
Fig. 17 Parkinson’s disease treatment market: Distribution channel outlook and key takeaways
Fig. 18 Parkinson’s disease treatment market: Distribution channel movement analysis
Fig. 19 Hospital Pharmacy market estimates and forecast, 2018-2030 (USD Million)
Fig. 20 Retail Pharmacy market estimates and forecast, 2018-2030 (USD Million)
Fig. 21 Online Pharmacy market estimates and forecast, 2018-2030 (USD Million)
Fig. 22 North America Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 U.S. Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Canada Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Mexico Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Europe Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 UK. Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Germany Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 France Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Italy Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Spain Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Denmark Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Sweden Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Norway Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Asia Pacific Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Japan Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 China Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 India Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Australia Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Thailand Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 South Korea Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Latin America Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Brazil Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Argentina Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 MEA Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 South Africa Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Saudi Arabia Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 UAE Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Kuwait Parkinson’s disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 List of key emerging companies/disruptors/innovators